NICE recommends GSK's Tafinlar in final guidance
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has given the final go-ahead for GlaxoSmithKline's melanoma drug Tafinlar (dabrafenib) to be used on the NHS.